Non classé
EuropaColon Slovenia wins Wolfram Nolte Memorial Award for Carer Support Initiative
EuropaColon Slovenia has won the Wolfram Nolte Memorial Award and €5,000 for its Heart to Heart Carer Support Programme, helping family carers of...
WHO Sounds the Alarm: Antibiotic Resistance Endangers Cancer Care
The World Health Organisation has sounded the alarm over a rising tide of antibiotic resistance, with one in six common bacterial infections worldw...
Pancreatic Cancer Across Europe: Progress and Next Steps
Work on pancreatic cancer has continued since the Position Paper was shared ahead of the 2024 European elections. With the new Parliament in place,...
Shaping Digestive Health Together: Insights from UEG’s Digestive Health Roundtable 2025
At UEG Week 2025, the Digestive Health Roundtable brought together patient leaders and healthcare professionals to address Europe’s growing diges...
Cork2Cong Challenge: Walking 250km to Raise Awareness of Pancreatic Cancer
Irish hotelier Niall Rochford will walk 250km from Cork to Cong this October in memory of his late wife, raising funds and awareness for Pancreatic...
IGET Celebrates Five Years of Advancing Gastrointestinal Cancer Care in Croatia
On 29 November 2025, the Institute for Gastroenterological Tumours (IGET), Zagreb, Croatia, will celebrate its fifth anniversary during Gastric Can...
Progress in Liver and Bile Duct Cancer: New Insights from ESMO 2025
This year’s ESMO Congress showcased key advances in the treatment of liver and bile duct cancers. While some new immunotherapy combinations did n...
Advancing Patient-Centred Care at UEG Week 2025
UEG Week 2025 in Berlin provided a valuable chance to deepen collaboration with healthcare professionals, researchers, and patient advocates. The f...
EU HTA Has Begun: What New Joint Clinical Assessments Mean for Access to Digestive Cancer Medicines
From 12 January 2025, new oncology medicines will undergo EU-wide Joint Clinical Assessments (JCAs). This coordinated evaluation aims to accelerate...
Key Takeaways from ESMO GI 2025 on Pancreatic Cancer
Promising new therapies are emerging. Daraxonrasib, a KRAS-targeting pill, is in Phase 3 trials after earlier encouraging results and FDA Breakthro...